| Literature DB >> 24330576 |
Hiroki Fujii, Masanori Iwase1, Toshiaki Ohkuma, Shinako Ogata-Kaizu, Hitoshi Ide, Yohei Kikuchi, Yasuhiro Idewaki, Tamaki Joudai, Yoichiro Hirakawa, Kazuhiro Uchida, Satoshi Sasaki, Udai Nakamura, Takanari Kitazono.
Abstract
BACKGROUND: Dietary fiber is beneficial for the treatment of type 2 diabetes mellitus, although it is consumed differently in ethnic foods around the world. We investigated the association between dietary fiber intake and obesity, glycemic control, cardiovascular risk factors and chronic kidney disease in Japanese type 2 diabetic patients.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24330576 PMCID: PMC3878841 DOI: 10.1186/1475-2891-12-159
Source DB: PubMed Journal: Nutr J ISSN: 1475-2891 Impact factor: 3.271
Characteristics of the studied participants and correlations with dietary fiber intake
| Number | 4,399 | | |
| Dietary fiber intake (g/1,000 kcal) | 7.60 ± 0.03 | - | |
| Fiber from vegetables (%) | 47.1 ± 0.2 | 0.42* | <0.0001 |
| Fiber from cereals (%) | 22.5 ± 0.2 | −0.60* | <0.0001 |
| Fiber from legumes and beans (%) | 11.8 ± 0.1 | 0.11* | <0.0001 |
| Fiber from fruits (%) | 9.5 ± 0.1 | 0.15* | <0.0001 |
| Age (years) | 65.4 ± 0.2 | 0.18* | <0.0001 |
| Sex (male, %) | 56.7 | 0.76 [0.74-0.78]# | <0.0001 |
| Duration of diabetes (years) | 15.5 ± 0.2 | 0.00* | ns |
| Current smoker (%) | 18.3 | 0.79 [0.76-0.82]# | <0.0001 |
| Current drinker (%) | 38.8 | 0.77 [0.74-0.79]# | <0.0001 |
| Total energy intake (kcal) | 1689 ± 7 | −0.12* | <0.0001 |
| Fat intake (g/day) | 52.4 ± 0.3 | 0.09* | <0.0001 |
| Saturated fatty acid intake (g/day) | 12.3 ± 0.1 | −0.08* | <0.0001 |
| Protein intake (g/day) | 67.3 ± 0.4 | 0.04* | 0.006 |
| Leisure-time physical activity (met▪hr/week) | 11.8 ± 0.2 | 0.12* | <0.0001 |
| Depressive symptoms (%) | 8.9 | 0.95 [0.90-0.99]# | 0.035 |
| Oral hypoglycemic agents (%) | 64.1 | 0.99 [0.96-1.01]# | ns |
| Insulin therapy (%) | 27.1 | 0.98 [0.95-1.01]# | ns |
Mean ± SE. *correlation coefficient, #odds ratio with 95% CI.
Multiple regression analysis of dietary fiber intake with clinical and laboratory variables
| Body mass index (kg/m2) | 23.8 ± 0.06 | −0.18 [−0.24,-0.11] | <0.0001 |
| Waist circumference (cm) | 85.9 ± 0.2 | −0.56 [−0.73,-0.39] | <0.0001 |
| Fasting plasma glucose (mmol/l) | 7.73 ± 0.03 | −0.049 [−0.084,-0.014] | 0.007 |
| HbA1c (%) | 7.42 ± 0.02 | −0.022 [−0.038,-0.005] | 0.009 |
| HbA1c (mmol/mol) | 57.6 ± 0.2 | −0.24 [−0.42,-0.06] | 0.009 |
| Fasting serum C-peptide (nmol/l) | 0.402 ± 0.003 | −0.009 [−0.013,-0.006] | <0.0001 |
| HOMA2%-B | 45.7 ± 0.4 | −0.26 [−0.68, 0.17] | ns |
| HOMA2%-S | 106.0 ± 0.6 | 1.95 [1.27, 2.62] | <0.0001 |
| Adiponectin (μg/ml)* | 9.1 [8.9-9.2] | 0.006 [−0.003, 0.016] | ns |
| HS-CRP (mg/l)* | 0.50 [0.48-0.52] | −0.067 [−0.090,-0.043] | <0.0001 |
| Total cholesterol (mmol/l) | 4.99 ± 0.01 | 0.009 [−0.005, 0.023] | ns |
| LDL cholesterol (mmol/l) | 2.87 ± 0.01 | 0.010 [−0.002, 0.022] | ns |
| HDL cholesterol (mmol/l) | 1.47 ± 0.01 | 0.008 [0.001, 0.014] | 0.017 |
| Triglyceride (mmol/l)* | 1.22 [1.20-1.24] | −0.013 [−0.022,-0.005] | 0.003 |
| Systolic blood pressure (mmHg) | 130.7 ± 0.3 | −0.35 [−0.64,-0.06] | 0.017 |
| Diastolic blood pressure (mmHg) | 74.7 ± 0.2 | −0.05 [−0.22, 0.13] | ns |
| Urinary albumin excretion (mg/g) | 28.2 [26.8-29.7] | −0.092 [−0.121,-0.063] | <0.0001 |
| eGFR (ml/min/1.73 m2) | 75.0 ± 0.3 | 0.34 [0.01, 0.67] | 0.042 |
Mean ± SE. *Geometric means with 95% CI in brackets. HOMA2-%B, homeostasis model assessment β-cell function; HOMA2-%S, homeostasis model assessment insulin sensitivity; HS-CRP, high sensitivity-C reactive protein; eGFR, estimated glomerular filtration rate. The multivariate adjustment included age, sex, duration of diabetes, current smoking habits, current drinking habits, total energy intake, fat intake, saturated fatty acid intake, protein intake (only for urinary albumin excretion and eGFR), leisure time physical activity and use of oral hypoglycemic agents or insulin.
Multiple logistic analysis between metabolic syndrome and dietary fiber intake
| Elevated waist circumference | Model | 0.90 [0.87-0.94] | <0.0001 |
| | Model + obesity | 0.93 [0.89-0.97] | 0.002 |
| Elevated blood pressure | Model | 0.93 [0.89-0.97] | 0.0002 |
| | Model + obesity | 0.94 [0.91-0.98] | 0.006 |
| Elevated triglyceride | Model | 0.97 [0.93-1.00] | ns |
| | Model + obesity | 0.98 [0.95-1.02] | ns |
| Low HDL cholesterol | Model | 0.97 [0.93-1.01] | ns |
| | Model + obesity | 0.98 [0.93-1.02] | ns |
| Metabolic syndrome | Model | 0.92 [0.89-0.96] | <0.0001 |
| Model + obesity | 0.95 [0.91-0.99] | 0.009 |
Obesity: BMI ≥25.0 kg/m2; Elevated waist circumference, waist circumference ≥90 cm in males and ≥80 cm in females; Elevated blood pressure, systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg and/or the use of antihypertensive drugs; Elevated triglyceride, fasting serum triglyceride ≥1.69 mmol/l and/or the use of triglyceride-lowering drugs; Low HDL cholesterol, fasting serum HDL cholesterol <1.03 mmol/l in males and <1.29 mmol/l in females. Metabolic syndrome was defined according to the definition of “Harmonizing the Metabolic Syndrome.” Model, multivariate adjustments with age, sex, duration of diabetes, current smoking habits, current drinking habits, total energy intake, fat intake, saturated fatty acid intake, leisure time physical activity and use of oral hypoglycemic agents or insulin.
Multiple logistic analysis between chronic kidney disease and dietary fiber intake
| Albuminuria ≥30 mg/g | Model | 0.92 [0.88-0.95] | <0.0001 |
| | Model + obesity | 0.93 [0.89-0.96] | <0.0001 |
| | Model + elevated blood pressure | 0.93 [0.89-0.96] | <0.0001 |
| | Model + metabolic syndrome | 0.93 [0.89-0.96] | <0.0001 |
| eGFR < 60 ml/min/1.73 m2 | Model | 0.94 [0.90-0.98] | 0.006 |
| | Model + obesity | 0.95 [0.90-0.99] | 0.015 |
| | Model + elevated blood pressure | 0.95 [0.91-0.99] | 0.019 |
| | Model + metabolic syndrome | 0.95 [0.91-0.99] | 0.027 |
| Chronic kidney disease | Model | 0.93 [0.90-0.96] | <0.0001 |
| | Model + obesity | 0.94 [0.90-0.97] | 0.0005 |
| | Model + elevated blood pressure | 0.94 [0.91-0.97] | 0.0009 |
| Model + metabolic syndrome | 0.94 [0.91-0.98] | 0.0011 |
Obesity: BMI ≥25.0 kg/m2; Elevated waist circumference, waist circumference ≥90 cm in males and ≥80 cm in females; Elevated blood pressure, systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg and/or the use of antihypertensive drugs; Elevated triglyceride, fasting serum triglyceride ≥1.69 mmol/l and/or the use of triglyceride-lowering drugs; Low HDL cholesterol, fasting serum HDL cholesterol <1.03 mmol/l in males and <1.29 mmol/l in females. Metabolic syndrome was defined according to the definition of “Harmonizing the Metabolic Syndrome.” Model, multivariate adjustments with age, sex, duration of diabetes, current smoking habits, current drinking habits, total energy intake, fat intake, saturated fatty acid intake, protein intake, leisure time physical activity and use of oral hypoglycemic agents or insulin.